Report overview
This report contains market size and forecasts of Hemoglobinopathies Drugs in global, including the following market information:
Global Hemoglobinopathies Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Hemoglobinopathies Drugs Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Hemoglobinopathies Drugs companies in 2021 (%)
The global Hemoglobinopathies Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Thalassemia Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hemoglobinopathies Drugs include Gamida Cell, Alnylam Pharmaceuticals, Biogen Idec, Sangamo BioSciences Inc., Genetix Pharmaceuticals/Bluebird Bio, Global Blood Therapeutics Inc., Pfizer Inc., Mast Therapeutics and Emmaus Life Sciences, Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hemoglobinopathies Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hemoglobinopathies Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Hemoglobinopathies Drugs Market Segment Percentages, by Type, 2021 (%)
Thalassemia Therapy
Sickle Cell Disease(SCD) Therapy
Other Therapy
Global Hemoglobinopathies Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Hemoglobinopathies Drugs Market Segment Percentages, by Application, 2021 (%)
Alpha Thalassemia
Beta thalassemia
Sickle Cell Disease
Hb Variants Diseases
Global Hemoglobinopathies Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Hemoglobinopathies Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hemoglobinopathies Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Hemoglobinopathies Drugs revenues share in global market, 2021 (%)
Key companies Hemoglobinopathies Drugs sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Hemoglobinopathies Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Gamida Cell
Alnylam Pharmaceuticals
Biogen Idec
Sangamo BioSciences Inc.
Genetix Pharmaceuticals/Bluebird Bio
Global Blood Therapeutics Inc.
Pfizer Inc.
Mast Therapeutics
Emmaus Life Sciences, Inc.
Prolong Pharmaceuticals
Celgene Corporation
HemaQuest Pharmaceuticals
